Bio/Pharma News

Merck KGaA plans to build a new biomanufacturing facility in Nantong, China.

Manufacturing of products made at the Barceloneta, Puerto Rico plant will be moved to other sites.

Shire-s agreement to acquire ViroPharma will strengthen its rare-disease portfolio.

Former President Jimmy Carter and Pfizer mark milestone for long-standing partnership to combat trachoma in the developing world.

ISPE names Novartis' US Flu Cell Culture facility as award winner.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Allegations include off-label marketing for Risperdal, Invega and Natrecor and kickbacks to doctors and pharmacists.

GSK and the Gates Foundation will invest a combined $1.8 million in early stage research into vaccine thermostability.

Zhoydro ER is the first drug to have updated labeling now required for all ER/LA opioid analgesics.

Big pharma companies Novartis, Amgen, and Bristol-Myers Squibb announce positive third-quarter 2013 results.

Amarin cuts staff in half after an FDA committee rejects its product label expansion.

FDA has awarded 15 grants totaling more than $14 million to boost the development of products for patients with rare diseases.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

GlaxoSmithKline?s sale of its thrombosis brands is part of a focus on its late-stage pipeline.

Merck announced plans to reduce its workforce by 8,500 and move its headquarters in order to sharpen its commercial and R&D focus.

Ablynx and AbbVie sign license agreement for Anti-IL-6R Nanobody, ALX-0061 to treat inflammatory diseases.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

Merck & Co. has received a Complete Response Letter from FDA for the resubmission of its new drug application for sugammadex sodium injection.

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.

GSK reported that the Court of Appeals has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza.

AstraZeneca and Merck & Co. form a licensing agreement for Merck?s oral small-molecule drug for ovarian cancer.

Sanofi withdraws its new drug application (NDA) in the US for lixisenatide and plans to file a NDA in 2015.

Novartis? half-billion dollar investment in a new biologics production plant in Singapore represents a strategic commitment to its growing biologics portfolio.

Baxter and Coherus Biosciences colaborate to develop and commercialize a biosimilar version of etanercept for Europe, Canada, and, Brazil.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Johnson & Johnson completes acquisition deal with Aragon Pharmaceuticals.

James Stewart named CIO of Merck KGaA.

The Russian pharmaceutical company PharmaStand finalizes deal for acquiring Bever, a Singapore pharma company.